DE69833297D1 - Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS) - Google Patents

Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)

Info

Publication number
DE69833297D1
DE69833297D1 DE69833297T DE69833297T DE69833297D1 DE 69833297 D1 DE69833297 D1 DE 69833297D1 DE 69833297 T DE69833297 T DE 69833297T DE 69833297 T DE69833297 T DE 69833297T DE 69833297 D1 DE69833297 D1 DE 69833297D1
Authority
DE
Germany
Prior art keywords
pyridylmethylpiperazine
cns
diseases
substituted
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833297T
Other languages
English (en)
Other versions
DE69833297T2 (de
Inventor
R W Feenstra
Hartog J A J Den
C G Kruse
M T M Tulp
S K Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of DE69833297D1 publication Critical patent/DE69833297D1/de
Application granted granted Critical
Publication of DE69833297T2 publication Critical patent/DE69833297T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DE69833297T 1997-09-24 1998-09-21 Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS) Expired - Lifetime DE69833297T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202950 1997-09-24
EP97202950 1997-09-24

Publications (2)

Publication Number Publication Date
DE69833297D1 true DE69833297D1 (de) 2006-04-13
DE69833297T2 DE69833297T2 (de) 2006-07-20

Family

ID=8228755

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833297T Expired - Lifetime DE69833297T2 (de) 1997-09-24 1998-09-21 Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)

Country Status (31)

Country Link
US (2) US6090812A (de)
EP (1) EP0908458B1 (de)
JP (1) JP4191826B2 (de)
KR (1) KR100632188B1 (de)
CN (1) CN1093857C (de)
AR (1) AR017127A1 (de)
AT (1) ATE316529T1 (de)
AU (1) AU733526B2 (de)
BR (1) BR9803497A (de)
CA (1) CA2247734C (de)
CY (1) CY1107494T1 (de)
CZ (1) CZ296741B6 (de)
DE (1) DE69833297T2 (de)
DK (1) DK0908458T3 (de)
DZ (1) DZ2613A1 (de)
ES (1) ES2255127T3 (de)
HK (1) HK1018272A1 (de)
HU (1) HU227422B1 (de)
ID (1) ID20895A (de)
IL (1) IL126295A (de)
NO (1) NO312835B1 (de)
NZ (1) NZ331984A (de)
PL (1) PL190622B1 (de)
PT (1) PT908458E (de)
RU (1) RU2197488C2 (de)
SI (1) SI0908458T1 (de)
SK (1) SK285205B6 (de)
TR (1) TR199801866A1 (de)
TW (1) TW530054B (de)
UA (1) UA66756C2 (de)
ZA (1) ZA988749B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
EP1140919B1 (de) * 1999-01-07 2002-09-04 Wyeth 1,4-disubstitutierte cyclohexanderivate zur behandlung von depression
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2003007956A1 (en) 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US20070275977A1 (en) * 2006-05-02 2007-11-29 Van Aar Marcel P N-oxides of pyridylmethyl -piperazine and -piperidine derivatives
CN101432279A (zh) 2006-05-02 2009-05-13 索尔瓦药物有限公司 吡啶基甲基哌嗪和吡啶基甲基哌啶衍生物的n-氧化物
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
WO2011088838A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands
US8877778B2 (en) * 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
TWI806385B (zh) 2016-07-20 2023-06-21 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
KR101665971B1 (ko) 2016-08-10 2016-10-13 (주)글로벌 로보틱스 차량용 발포패드 부착장치
MX2022006176A (es) 2019-11-22 2022-08-17 Incyte Corp Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
EP4164641A1 (de) 2020-06-16 2023-04-19 Incyte Corporation Alk2-inhibitoren zur behandlung von anämie

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
EP0185429A1 (de) * 1984-12-21 1986-06-25 Duphar International Research B.V Bizyklische Piperazine
IL81669A (en) * 1986-02-27 1990-11-29 Duphar Int Res Aryl-substituted(n-piperidinyl)methyl-and(n-piperazinyl)-methylazoles,their preparation and pharmaceutical compositions containing them
EP0508347A1 (de) 1991-04-10 1992-10-14 Hoechst Aktiengesellschaft 5,7-Dihydroxy-2-Methyl-8-[4-(3-Hydroxy-1-(1-Propyl))Piperidinyl]-4H-1-Benzopyran-4-on, seine Herstellung und Verwendung
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH05262765A (ja) 1992-03-18 1993-10-12 Sumitomo Chem Co Ltd ベンゾフラン誘導体およびそれを有効成分とする除草剤
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
EP0650964A1 (de) 1993-11-02 1995-05-03 Duphar International Research B.V 1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
AU6517196A (en) * 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
AU708053B2 (en) * 1996-03-29 1999-07-29 Duphar International Research B.V. Piperazine and piperidine compounds
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
KR100632188B1 (ko) 2007-04-25
BR9803497A (pt) 2000-05-02
USRE41425E1 (en) 2010-07-06
IL126295A0 (en) 1999-05-09
SK129498A3 (en) 1999-04-13
US6090812A (en) 2000-07-18
NO984380D0 (no) 1998-09-21
ID20895A (id) 1999-03-25
JP4191826B2 (ja) 2008-12-03
CN1093857C (zh) 2002-11-06
CA2247734A1 (en) 1999-03-24
HU9802129D0 (en) 1998-11-30
HU227422B1 (en) 2011-05-30
DK0908458T3 (da) 2006-06-06
PT908458E (pt) 2006-05-31
TR199801866A1 (xx) 1999-04-21
EP0908458B1 (de) 2006-01-25
PL190622B1 (pl) 2005-12-30
ATE316529T1 (de) 2006-02-15
CA2247734C (en) 2007-08-07
KR19990029982A (ko) 1999-04-26
HUP9802129A1 (hu) 2000-03-28
EP0908458A1 (de) 1999-04-14
AR017127A1 (es) 2001-08-22
AU733526B2 (en) 2001-05-17
DE69833297T2 (de) 2006-07-20
ES2255127T3 (es) 2006-06-16
NZ331984A (en) 2000-02-28
NO984380L (no) 1999-03-25
SI0908458T1 (sl) 2006-06-30
CZ303098A3 (cs) 1999-04-14
DZ2613A1 (fr) 2003-03-01
CY1107494T1 (el) 2013-03-13
IL126295A (en) 2003-02-12
PL328754A1 (en) 1999-03-29
CZ296741B6 (cs) 2006-06-14
CN1220265A (zh) 1999-06-23
SK285205B6 (sk) 2006-08-03
AU8607998A (en) 1999-04-15
HK1018272A1 (en) 1999-12-17
NO312835B1 (no) 2002-07-08
TW530054B (en) 2003-05-01
JPH11302279A (ja) 1999-11-02
UA66756C2 (uk) 2004-06-15
ZA988749B (en) 1999-03-26
RU2197488C2 (ru) 2003-01-27

Similar Documents

Publication Publication Date Title
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69623992T2 (de) Derivate von dolestatin, deren herstellung und verwendung
DE69720463T2 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE69212620T2 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69029231D1 (de) Indolderivate, ihre herstellung und diese enthaltendes arzneimittel zum verhindern und behandeln von nephritis
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69027170D1 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
ATE304542T1 (de) Substituierte (1,3-bis(cyclohexylmethyl)-1,2,3,6- tetrahydro-2,6-dioxo-9h-purin-8yl)phenyl derivate,deren herstellung und deren verwendung in der behandlung von entzündungen und immunkrankheiten
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
DE69716896T2 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE59711704D1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
DE69517768D1 (de) IMIDAZOLYLALKYLDERIVATE VON IMIDAZO [5,1-c][1,4]BENZOXAZIN-1-ON UND IHRE VERWENDUNG ALS ARZNEIMITTEL
DE69611303T2 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE68900867D1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition